Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
The IPO Market is poised to resume its long-awaited pickup in 2026. Here’s what you need to know to stay on top of the year ahead. The IPO market continued its gradual recovery in 2025. New issuance reached a four-year high, and demand for disruptive...read more
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
IPO Outlook: The short list of the biggest deals expected in 2026
The IPO Market is poised to resume its long-awaited pickup in 2026. Here’s what you need to know to stay on top of the year ahead. The IPO market continued its gradual recovery in 2025. New issuance reached a four-year high, and demand for disruptive...read more
Renaissance Capital's November IPO Market Update
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more